Arcus Biosciences Stock In The News
| RCUS Stock | USD 15.95 0.45 2.90% |
Our overall analysis of Arcus Biosciences' news coverage and content from conventional and social sources shows investors' bearish mood towards Arcus Biosciences. The specific impact of Arcus Biosciences news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Arcus Biosciences' overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Arcus Biosciences headlines in addition to utilizing other, more conventional financial analysis modules. Check out Arcus Biosciences Backtesting and Arcus Biosciences Hype Analysis. For more information on how to buy Arcus Stock please use our How to Invest in Arcus Biosciences guide.
Arcus |
Arcus Biosciences Today Top News and Investor Outlook
Arcus Biosciences Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Arcus and other traded companies coverage with news coverage. We help investors stay connected with Arcus headlines for the 24th of December to make an informed investment decision based on correlating the impacts of news items on Arcus Stock performance. Please note that trading solely based on the Arcus Biosciences hype is not for everyone as timely availability and quick action are needed to avoid losses.
Arcus Biosciences stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Arcus earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Arcus Biosciences that are available to investors today. That information is available publicly through Arcus media outlets and privately through word of mouth or via Arcus internal channels. However, regardless of the origin, that massive amount of Arcus data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Arcus Biosciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Arcus Biosciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Arcus Biosciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Arcus Biosciences alpha.
Arcus Largest EPS Surprises
Earnings surprises can significantly impact Arcus Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2020-11-05 | 2020-09-30 | 0.05 | 0.03 | -0.02 | 40 | ||
2019-05-02 | 2019-03-31 | -0.35 | -0.41 | -0.06 | 17 | ||
2020-05-05 | 2020-03-31 | -0.56 | -0.63 | -0.07 | 12 | ||
2018-08-06 | 2018-06-30 | -0.4 | -0.32 | 0.08 | 20 | ||
2022-05-09 | 2022-03-31 | -0.86 | -0.96 | -0.1 | 11 | ||
2020-03-05 | 2019-12-31 | -0.51 | -0.38 | 0.13 | 25 |
Arcus Biosciences Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Arcus Biosciences Stock. The global stock market is bullish. About 65% of major world exchanges and indexes are currently up. See today's market update for more information.
20th of December 2024
Shareholders in Arcus Biosciences have lost 65, as stock drops 9.9 percent this past week at finance.yahoo.com
10th of December 2024
Arcus Biosciences Inc Announces Equity Awards for New Employees at gurufocus.com
3rd of December 2024
Arcus Biosciences Grants New Employee Stock Options and RSUs in Latest Inducement Awards R... at news.google.com
19th of November 2024
Arcus Biosciences to Present at Evercore and Citi Healthcare Conferences in December RCUS ... at news.google.com
7th of November 2024
Q3 2024 Arcus Biosciences Inc Earnings Call Transcript at gurufocus.com
6th of November 2024
Arcus Biosciences GAAP EPS of -1.00 beats by 0.04, revenue of 48M beats by 9.05M at seekingalpha.com
5th of November 2024
Arcus Biosciences Announces that Domvanalimab Plus Zimberelimab Improved Overall Survival ... at businesswire.com
31st of October 2024
Regeneron Tops Q3 Earnings and Revenue Estimates at zacks.com
9th of October 2024
Arcus Biosciences, Inc.s Intrinsic Value Is Potentially 30 percent Above Its Share Price at finance.yahoo.com
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Arcus Biosciences in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Arcus Biosciences' short interest history, or implied volatility extrapolated from Arcus Biosciences options trading.
Additional Tools for Arcus Stock Analysis
When running Arcus Biosciences' price analysis, check to measure Arcus Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcus Biosciences is operating at the current time. Most of Arcus Biosciences' value examination focuses on studying past and present price action to predict the probability of Arcus Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcus Biosciences' price. Additionally, you may evaluate how the addition of Arcus Biosciences to your portfolios can decrease your overall portfolio volatility.